Research and Markets: Australia Pharmaceutical Market Overview - Reforms and Continued Price Cuts Will Change the $80 Bill

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape" report to their offering.

Australia Pharmaceutical Market Overview - Reforms and Continued Price Cuts Will Change the $80 Billion Healthcare Landscape

The prescription pharmaceutical market in Australia was valued at $9.1 billion in 2009. Key growth drivers include the growing use of chronic high-value innovative treatments driven by a rising elderly population and high public spending as a proportion of total healthcare expenditure.


  • Overview of Australia's socioeconomics and demographics, healthcare system, regulation, pricing and reimbursement and intellectual property position.
  • Assesses the size of Australia's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies.
  • Examines Australia's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion.
  • Quantifies Australia's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis.

Highlights of this title

  • Australia's health expenditure totaled $81.8 billion, representing 9.1% of gross domestic product (GDP) in the financial year of 2007-08, which is the same percentage of GDP as the previous year. Australia's health expenditure as a proportion of GDP has been comparable to that seen in Europe, with most of its spending coming from the government.
  • Lipitor (atorvastatin, Pfizer) generated significantly higher sales than any other brand on the Australian pharmaceutical market in 2009 ($550m). The second and third highest-selling brands, Crestor (rosuvastatin; AstraZeneca) and Nexium (esomeprazole; AstraZeneca), lag far behind Lipitor and did not even reach half of its sales.
  • Compared with Europe, where 17 biosimilars of five different molecules have been approved since 2006, Australia's biosimilar market is small, particularly in terms of sales at $45,000. Somatropin is the only biologic that has biosimilar versions available, although the market is still very much dominated by the original branded product.

Key reasons to purchase this title

  • Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.
  • Quantify the size and growth of the prescription pharmaceutical market in Australia, analyzing key therapy areas, brands and companies.
  • Assess drivers and resistors of generic and biosimilars uptake in Australia and the level of erosion brands can expect to face post patent expiry.

Key Topics Covered:

1. Australia - Executive Summary 2. Australia - Socio-demographic and economic Analysis

3. Australia - Healthcare system and drug regulatory analysis

4. Australia - Prescription pharmaceutical sales analysis 5. Australia - Drug expiry analysis

6. Australia - Pharmaceutical industry infrastructure analysis

7. Bibliography

Companies mentioned:

  • Pfizer
  • AstraZeneca
  • Sanofi-Aventis
  • GlaxoSmithKline
  • Novartis
  • Merck & Co.
  • Johnson & Johnson
  • Sigma Pharmaceuticals
  • Roche
  • Mylan

For more information visit

Source: Datamonitor


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Australia  Australia/Oceania

INDUSTRY KEYWORDS:   Health  Pharmaceutical